TY - JOUR T1 - Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer. AU - Smolarz,Beata, AU - Romanowicz-Makowska,Hanna, AU - Kulig,Andrzej, PY - 2002/04/22/received PY - 2003/04/22/revised PY - 2003/05/19/accepted PY - 2003/7/2/pubmed PY - 2004/6/2/medline PY - 2003/7/2/entrez SP - 489 EP - 95 JF - Acta biochimica Polonica JO - Acta Biochim Pol VL - 50 IS - 2 N2 - Plasminogen activator inhibitor 1 (PAI-1) content in colorectal cancer tissue extracts may be of strong prognostic value: high levels of PAI-1 in tumours predict poor prognosis. The gene encoding PAI-1 is highly polymorphic and PAI-1 gene variability could contribute to the level of PAI-1 biosynthesis. In the present work the distribution of genotypes and frequency of alleles of the 1334G/A polymorphism in 92 subjects with colorectal cancer in samples of cancer tissue and distant mucosa samples as well as in blood were investigated. Blood samples age matched healthy individuals (n = 110) served as control. The 1334G/A polymorphism was determined by PCR amplification using allele specific primers. No differences in the genotype distributions and allele frequencies between blood, distant mucosa samples and cancer tissue were detected. However, the distribution of the genotypes of the 1334G/A polymorphism in patients differed significantly (P <0.05) from those predicted by the Hardy-Weinberg equilibrium. There were significant differences in the frequencies of alleles between the colorectal cancer subjects and controls (P <0.05). The results support the hypothesis that the 1334G/A polymorphism may be associated with the incidence of colorectal cancer. SN - 0001-527X UR - https://www.unboundmedicine.com/medline/citation/12833173/Plasminogen_activator_inhibitor_1__PAI_1__1334G/A_genetic_polymorphism_in_colorectal_cancer_ DB - PRIME DP - Unbound Medicine ER -